|PO Box 8009 , Boston, MA 02266|
|Fund Manager||Team Managed|
The Lifecycle 2010 Fund seeks high total return over time through a combination of capital appreciation and income. The Fund is a "fund of funds" that invests in Class W shares of other funds of the Trust and in other investment pools or investment products, potentially including other funds advised by the Fund's investment adviser, Teachers Advisors, LLC ("Advisors"), or its affiliates (collectively, the "Underlying Funds"). In general, the Fund is designed for investors who have an approximate target retirement year in mind, and the Fund's investments are adjusted from more aggressive to more conservative over time as the Fund's target retirement year approaches and for approximately 30 years afterwards. The Fund invests in Underlying Funds according to an asset allocation strategy designed for investors who retired in, or planned to retire within a few years of, 2010 and may have begun taking systematic withdrawals upon retirement.
|Asset Type||% Of Allocation|
|Total Net Assets||81.53 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$0|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 06/30/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 06/30/2021|
|Life Of Fund||
Join the Action Alerts PLUS Community today!
Ahead of third-quarter earnings season, James 'Rev Shark' Deporre has some thoughts on what investors should be thinking about.
Gogo, Huntsman, Thor Industries, United Natural Foods and Sonoma Pharmaceuticals are five top stock gainers for Tuesday.
Stocks are lower as Wall Street contends with rolling blackouts in China, record high energy prices in Europe and gas line-ups in Britain.
Aurora Cannabis had a tough quarter, but Cowen analysts still expect strong growth margins in 2022.
'Redwire offers a diversified portfolio of space components that are well-positioned to capture emerging trends,' Jefferies says.
Uncertain fiscal and monetary policies could prompt a stock correction, the noted bull Phil Orlando says.
Sanofi says its COVID vaccine candidate has positive test results, but the company is ready to drop its development because of the Moderna and Pfizer vaccines.